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A B S T R A C T
This report describes the clinical value of transrectal prostate biopsy during which
12 biopsy cores are taken in comparison to the classical sextant method. There were 106
patients included in the study, who had transrectal prostate biopsy (TRB) due to abnor-
mal finding after digitorectal examination (DRE) and/or values of PSA > 4 ng/ml in
the period from 4 October 2001 till 14 August 2002. There were 117 biopsies with 12 bi-
opsy cores taken, 6 cores from each lobe. Prostate cancer was confirmed in 49 patients
(46%). Out of total number of confirmed cancer cases, initial biopsy detected 94%. There
were three patients who had suspicious DRE finding, with PSA value of < 4 ng/ml, but
cancer was not detected in any of them. In the patient group with PSA value between
4–10 ng/ml, cancer was detected in 26% of them and in the group with PSA value > 10
ng/ml cancer was detected in 58%. The most common Gleason score in the case of can-
cer was 7 (43%). During the biopsy procedure, 3 patients experienced strong vasovagal
reactions, meaning that out of 117 biopsies incidence of complications was 2.6%. Few
days after the biopsy, two patients developed urogenital tract infections (1.7%) and right
after the procedure, there was one case of strong hematuria (0.8%) and strong rectal
bleeding (0,8%) that needed hospitalization. Our results regarding the incidence of com-
plications do not differ much from the results in the literature. According to data in the
literature regarding sextant biopsy, 15–34% of cancer cases remain undiagnosed at ini-
tial biopsy. The method of 12 biopsy cores fails to diagnose only 6% of all cancers, but it
is important to note that in the mentioned period, re-biopsy was indicated only in 11
from 60 patients with negative biopsies.
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Introduction
In last few decades the biopsy tech-
nique has improved much. The very first
one was finger guided puncture biopsy,
replaced by transperineal biopsy under
general anesthesia and nowadays we per-
form widely accepted transrectal ultra-
sound guided prostate biopsy. Hodge et
al. described sextant method of trans-
rectal biopsy in 1989 and now it is a stan-
dard procedure1. The procedure itself
consists of 6 biopsy cores taken from pros-
tate region where cancer more likely oc-
curs; so there are 3 cores taken form each
lobe, from apical, middle and basal part
of prostate in an appropriate parasagittal
line. Applying the procedure for years,
the urologist realized that the sextant
method had its shortcoming in cancer de-
tection. The main complain was a high
number of false negative cancer found af-
ter the initial biopsy what made doubtful
its accuracy and reliability. It turned out
that number of positive findings, mean-
ing number of undetected cancers after
the initial biopsy was rather high, rang-
ing from 15–34%2. Numerous studies
have tried to prove whether some chan-
ges of transrectal biopsy technique, in-
cluding the increase in number of biopsy
cores and change of prostate zones that
cores are taken from, could improve the
accuracy of the method in cancer detec-
tion. So far, there has not been found the
most suitable method which would meet
certain parameters (like significant in-
crease in detection of cancer but without
affecting increase in detection of clini-
cally insignificant cancer, without increa-
sing incidence of complications and not
affecting patients well-being) to replace
sextant method successfully.
This report presents our own results
obtained after transrectal biopsy of pros-
tate which includes taking of 12 biopsy
cores and we compared the results with
the those ones in the literature regarding
sextant biopsy.
Material and Methods
This report is a retrospective study,
showing the results of transrectal pros-
tate biopsy, consisting of 12 biopsy cores,
which were taken from October 2001 till
August 2002. In this time 106 patients
had transrectal biopsy and it was indi-
cated due to abnormal DRE finding and/
or due to PSA value of > 4 ng/ml.
In the past the standard biopsy tech-
nique, conducted at the Department of
Urology, University Hospital »Osijek«,
was a transperineal method which con-
sisted of 6 and later 12 biopsy cores. In
October 2001 we introduced the trans-
rectal biopsy method and did not perform
transperineal any more, except when the
transrectal method cannot be technically
performed (for e.g. if there are severe
hemorrhoid piles, or after abdominope-
rineal rectum resection) or when patient
is prone to infections (for e.g. serious dia-
betic patients, or patients with implanted
heart valves). We have had only one case
so far, a patient with abdominoperineal
rectum resection.
All patients were given written in-
structions at the examination prior to the
procedure, with detailed explanations of
the biopsy procedure and possible compli-
cations. It is emphasized that the proce-
dure does not require any other special
preparation of the patient, except to stop
with anticoagulant therapy 7 days before,
to have a full bladder and emptied colon
(but without laxative or enema) before
the biopsy. The patient must have a lab
analysis done, not older than a month.
Transrectal biopsy is done in outpatients,
without anesthesia. Prior to biopsy, pa-
tients are given an antibiotic prophylaxis.
The choice is intramuscular injection of
cefazolin (Kefzol) in a dose of 1 g, except
in the case of beta-lactam antibiotics al-
lergy. These patients are given fluoroqui-
nolone orally during 3–5 days after the
procedure.
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During the procedure the patient is ly-
ing in the left lateral position, with ben-
ded legs in hips and knees and the rectal
probe with needle guidance is inserted in
rectum. Prior to it, the probe is covered
with a condom, filled with ultrasound gel,
then the needle guidance is fixed on the
probe and then comes another condom
with gel over the entire instrument
(Brüel & Kjær Medical). Biopsy is per-
formed using an 18 Gauge biopsy needle
driven by a biopsy gun, which enables to
take 12 biopsy cores, 6 from right and 6
from left lobe. There are 3 cores from each
lobe as it is typical for classical sextant
method, with additional 3 cores from
each lobe which are pointing even more to
lateral parts of peripheral regions. We
can determine precisely which prostate
part we want to take samples from with
the help of the dotted line on the screen.
We usually take random, systematic co-
res, but if we visualize hypoechoic zones
in the prostate, we take a targeted sam-
ple which is already included in men-
tioned 6, actually 12 samples. One hour
after the procedure the patients could
empty their bladder and if there is no se-
vere hematuria, they are discharged, but
asked in the case of any complications to
come back to the hospital. However, tem-
porary hematuria, blood in stool and
sperm could be expected.
Results
Out of 106 patients who had biopsies
in the mentioned period, cancer was de-
tected in 49 patients (46%). Figure 1
shows distribution of patients according
to age and number of patients with can-
cer in each group. In 3 patients who un-
derwent biopsies due to suspicious DRE,
with PSA value of < 4ng/ml, no cancer
was detected. In the group of patients
who had PSA value of 4–10 ng/ml, cancer
was detected in 26%. The highest number
of patients had PSA > 10 ng/ml and can-
cer was detected in 40 of them (58%).
These results can be seen in the Table 1.
The most common Gleason score was 7
(43%). Figure 2 shows cancer distribution
according to the Gleason score. Two pa-
tients developed urogenital infections few
days after the procedure (one prostatitis
and one orchiepididymitis), meaning
1.7% of infection rate in 117 biopsies.
During the procedure in 3 patients vaso-
vagal reactions with loss of consciousness
occurred (2.6%), one patient had severe
hematuria (0.8%) and one had rectal
bleeding (0.8%) which has to be treated in
hospital. The complications are presented
in the Table 2.
All patients had at least one biopsy.
The cancer was detected with the initial
set in 46 cases (94%). In the mentioned
period, re-biopsy was indicated in 11 pa-
tients and in 3 patients the diagnosis was
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TABLE 1
DISTRIBUTION OF PATIENTS ACCORDING TO
PSA-VALUES AND NUMBER OF PATIENTS







< 4 3 0
4 – 10 34 9 (26)
































Fig. 1. Distribution of patients according to age
and number of patients with prostate cancer in
each age group.
cancer. These data show that our percent-
age of detected cancer with initial biopsy
is 94%, suggesting that we only did not
detect 6% of all detected (other patients
to whom re-biopsy was not indicated in
this period, were not included).
Discussion
We introduced transrectal prostate bi-
opsies at the time when the sextant pro-
tocol was exposed to strong criticism. Sin-
ce we had good results with transperineal
biopsies in taking 12 cores, we decided to
take 12 cores also in the case of trans-
rectal biopsy3,4. Out of all patients who
had biopsies, cancer was detected in 46%
patients and 94% of cancer cases was di-
agnosed by the first biopsy. We consider
this as a rather significant outcome in
comparison to the results obtained by
sextant biopsy because it fails to detect
15–34% clinically significant cancers
with the first biopsy set2. This high
percentage of positive re-biopsies in the
sextant protocol inspired creation of new
protocol in order to detect cancer more
successfully. These new techniques were
created as a result of the low accuracy of
the sextant method, which could not pro-
vide representative parts of prostate tis-
sue for pathohistological examination in
relation to prostate volume and could not
supply enough prostate tissue from lat-
eral parts of peripheral zone. The total
volume of 6 biopsy cores in case of larger
prostate is only a small portion of total
volume of prostate tissue and can be con-
sidered suboptimal, affecting likehood of
cancer detection5. Djavan et al. say that 6
cores are insufficient if the volume of the
prostate is higher than 45 grams, so in
the case when initial sextant biopsy is
negative, re-biopsy should be considered
as well6. The opinion of Uzzo et al. is that
if the volume of the prostate is lower than
50 grams, the percentage of cancer detec-
tion is 38%, but if prostate volume is
higher than 50 grams only 23%7. Eskew
et al. mentioned that increasing the num-
ber of the samples from 6 to 10, improves
the accuracy of cancer detection from 26%
to 40%8. Ravery et al. talk about im-
proved cancer detection after taking 10 or
12 samples unlike sextant method, espe-
cially among the patients whose PSA is >
10 ng/ml, normal DRE and prostate vol-
ume bigger than 50 grams9. On the con-
trary, Naughton et al. did not find a sig-
nificant difference in cancer detection
among the patients who had 6 cores ta-
ken (26%) and those who had 12 (28%)
cores taken10. It is undisputed that an in-
crease of bioptic samples from 4 to 6 im-
proves accuracy of cancer detection. Nev-
ertheless, there is no consensus how big
the number of samples should be and to
what extent it should be increased so that
cancer can be more successfully detected.
Some authors have improved the like-
hood of cancer detection once when they
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Fig. 2. Distribution of cancer according to
Gleason score.
TABLE 2




Vasovagal episodes 3 (2.6)
Severe hematuria 1 (0.8)
Rectal bleeding 1 (0.8)
increased the number of samples up to
1811. Vaski et al. and Djavan et al. have
suggested the so called Vienna nomo-
gram, so that the number of samples cor-
responds with prostate volume, patients'
age and should vary from 6–18. It is be-
lieved that this biopsy method improves
cancer detection up to 90%12. The increa-
sed number of the biopsy cores could
maybe increase the detection of clinically
insignificant cancers. In order to reach
that conclusion, serious analysis is re-
quired that would compare cancers from
one group with those of the other and
comparison criteria should include vol-
ume of tumor tissue and pathological tu-
mor stage (after radical prostatectomy),
DNA ploidia of tumor cells etc. Chan et
al. think that increased number of sam-
ples does not improve the likehood that
insignificant cancer would be detected,
but only helps to detect cancer in its ear-
lier stage13.
It is not clear whether the increased
number of cores in case of bigger prostate
volumes improves the likelihood of cancer
detection or it is more important of which
region of the prostate are the samples are
taken from. Norberg et al. have concluded
that sextant method successfully detects
82% of clinical significant cancers, but if
only 6 cores were taken along the sagittal
line which is more laterally than the line
cores are usually taken from in case of
sextant method, only 70% of the cancers
would be detected. The combination of
these two methods, taking 12 cores,
would improve detection up to 96%14. Our
protocol reflects exactly this core taking
and 94% of detected cancers with the ini-
tial biopsy, supports this theory.
Gretzer et al. consider that about 25%
of the patients who have PSA value be-
tween 4–10 ng/ml have cancer, as well as
67% of the patients with PSA > 10 ng/
ml15. Our results correspond with those
mentioned and show frequency of cancer
detection in 26% and 58% in appropriate
PSA groups. The same authors mention
that the likelihood of the cancer in the
group with PSA value of < 4ng/ml is about
18%, but we did not have enough patients
(only 3), so we could not compare the re-
sults. Studying the incidence of some
Gleason scores, we have noticed that in
6% of the cancers the Gleason score was
2–4, in 35% Gleason score was 5–6, in
59% Gleason score was 7–10. Emiliozzi et
al. mention a similar incidence in the
group of low, middle and high grade16.
Based on 117 biopsies we can say that
we had a 1.7% infection rate, 2.6% va-
sovagal episodes, 0.8% rectal bleedings
and 0.8% severe hematuria. The reported
complications required either an immedi-
ate treatment or hospitalization of the
patient. We did not keep a record of mild
complications, since they were short and
healed spontaneously. There were two pa-
tients who had urogenital infections few
days after the biopsy (1.7%). They were
successfully treated with antibiotics and
symptomatically. The infection has not
been clearly defined in the literature, as
some authors describe it as high tempera-
ture, fever, sepsis or symptoms of urogen-
ital tract infection. Sieber et al. report
0.1% of infection rate17 and Rodriguez et
al. about 2.5%18. The vasovagal reactions
we recorded included loss of conscious-
ness, drop of blood pressure that were
treated with i.v. infusions, but milder re-
actions included sweating, tachicardia,
moderate fall of blood pressure, without
loss of consciousness and fast recovery,
we did not include in the study. There
were 3 patients who suffered from these
severe reactions (2.6%). Djavan et al. men-
tion 2.8% of vasovagal episodes19. Spea-
king of hematuria, only one patient had
its severe form and was hospitalized
(0.8%). We hospitalized one patient due
to rectal bleeding (0.8%). Djavan et al. de-
scribe 0.5% of strong hematuria, 2.1% of
rectal bleeding19. As we have mentioned,
patients were informed about potential
247
M. Kne`evi} et al.: Transrectal Prostate Biopsy, Coll. Antropol. 28 Suppl. 2 (2004) 243–250
temporary hematuria and rectal bleed-
ing. Therefore we did not follow nor in-
clude milder cases of one or the other
complication, which in spite of being fre-
quent, heal fast and do not affect pa-
tient's well being.
Transrectal biopsy is performed with
no anesthesia, though most of the pa-
tients expressed slight discomfort or light
pain, there was no case of strong pain
that would force us to take less numbers
of samples. Administration of anesthesia
is still discussed during TRB and the
opinions are very different. There are
urologists who advice the administration
of local anesthesia for all patients and at
the same time the those who oppose to it,
saying that it is rather a pain tolerant
procedure and so no anesthesia should be
given. According to Aus et al. 92% of the
patients did not feel any pain or they felt
a slight discomfort20. Some authors think
that anesthesia should be given only
when more numbers of samples are ta-
ken, because they believe that pain is get-
ting worse when more samples are taken.
The opinion of Rodriguez et al. is young
people are more sensitive to pain and an-
esthesia should be applied18. There are
two most common types of local anesthe-
sia during TRB, intrarectal administra-
tion of lidocaine gel and periprostatic lo-
cal injection of lidocaine in neurovascular
bundle. Vaidya et al. think that peripro-
static anesthesia should be given to all
patients21. Leibovici et al. pointed out
that the patients who 10 ml of 1% lido-
cain had injected periprostatically, suf-
fered from less pain than patients who
were given placebo of 0.9% NaCl in pe-
riprostatic injection22. The results of the
studies discussing the use of lidocain rec-
tal gel are different. Issa et al. mention
that patients who were given gel suffered
from less pain than those who were not23.
Chang et al. do not share this point of
view because they have not notice better
pain tolerance in the group given gel than
in the one which had placebo24.
Conclusion
Despite of many authors suggesting
that increased number of biopsy cores im-
proves the detection of prostate cancer,
the biopsy protocol remains undefined. It
is not clear whether improved prostate
cancer detection after increasing number
of cores is a consequence of increased tis-
sue portion needed for pathohistological
examination, or it is more important of
which prostate regions the cores are ta-
ken from. The percentage of detected can-
cer on the first biopsy is 94%, justifying
our decision to continue with 12 biopsy
cores, especially because increased num-
ber of cores has not been accompanied
with higher incidence of complications.
However, what we should work on is to
improve the biopsy technique so that it is
suitable to every patient, regarding his
age, PSA value, prostate volume and fin-
ding of transrectal ultrasound in order to
avoid unnecessary increase of sample
numbers by some patients.
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REZULTATI DOBIVENI TRANSREKTALNIM BIOPSIJAMA PROSTATE
S UZIMANJEM 12 BIOPTI^KIH UZORAKA
S A @ E T A K
U ovom radu `elimo prikazati klini~ku vrijednost transrektalne biopsije prostate sa
uzimanjem 12 biopti~kih uzoraka u odnosu na klasi~nu sekstant metodu. Obradili smo
podatke 106 pacijenata, kod kojih smo od 4.10.2001. do 14.8.2002. godine u~inili trans-
rektalnu biopsiju prostate (TRB), koja je bila indicirana zbog abnormalnog nalaza digi-
torektalnog pregleda (DRE) i/ili vrijednosti PSA > 4 ng/ml. U navedenom periodu smo
u~inili 117 biopsija sa uzimanjem 12 biopti~kih uzoraka, po 6 uzoraka iz svakog poje-
dinog re`nja. Karcinom prostate smo dokazali kod 49 pacijenata (46%). Od ukupnog
broja dokazanih karcinoma, inicijalnom biopsijom smo dokazali 94%, {to zna~i da nam
je prilikom izvo|enja prve biopsije ostalo nedijagnosticirano samo 6% karcinoma. Kod
3 pacijenta biopsiju smo u~inili zbog suspektnog nalaza DRE uz vrijednost PSA < 4
ng/ml, no karcinom nismo dokazali niti kod jednog od njih. U skupini pacijenata koji su
imali PSA izme|u 4–10 ng/ml, karcinom smo dokazali kod njih 26%, a u skupini pa-
cijenata sa PSA > 10 ng/ml, karcinom smo dokazali kod 58%. Najzastupljeniji Gleason
score karcinoma je bio 7 (43%). Tijekom provo|enja biopsije, kod 3 pacijenta je do{lo do
izra`ene vazovagalne reakcije, {to na ukupno 117 u~injenih biopsija iznosi u~estalost
navedene komplikacije od 2.6%. U periodu od nekoliko dana nakon biopsije, kod 2 pa-
cijenta je do{lo do razvoja infekcije urogenitalnog trakta (1.7%), a neposredno nakon
provo|enja postupka, u po jednom slu~aju smo imali pojavu jake hematurije (0.8%) i
jakog rektalnog krvarenja (0.8%), koji su zahtijevali hospitalizaciju. Na{i podaci o po-
javi komplikacija se ne razlikuju zna~ajno u odnosu podatke o komplikacijama iz lite-
rature. Podaci iz literature za sekstant biopsije pokazuju da 15–34% karcinoma ostane
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nedijagnosticirano inicijalnom biopsijom. Metodom sa uzimanjem 12 biopti~kih uzora-
ka, inicijalnom biopsijom nismo uspjeli dijagnosticirati samo 6% od ukupno dokazanih
karcinoma, ali va`no je naglasiti da je u vremenskom periodu koji je obuhvatila ova
studija, re-biopsija bila indicirana samo u 11 pacijenata od svih sa negativnom ini-
cijalnom biopsijom.
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